|
||
“Facing Cancer, A Stark Choice.” By Tara Parker-Pope, The New York Times In the 1970s, women’s health advocates were highly suspicious of mastectomies. They argued that surgeons — in those days, pretty much an all-male club — were far too quick to remove a breast after a diagnosis of cancer, with disfiguring results. But today, . . . → Read More: Facing Cancer, A Stark Choice
“Living With Stage IV Breast Cancer.” By Algerina Perna, The Darkroom, a photography and video blog of The Baltimore Sun In September 2012, I photographed a group of women diagnosed with terminal stage IV breast cancer: Kay Campbell, Gretchen Carlquist, Dian “CJ” Corneliussen-James, Cecilia “Cece” Curry , and Sally Ring. As I photographed these women, . . . → Read More: Living With Stage IV Breast Cancer
“Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer.” By F.E. Vera-Badillo, R. Shapiro, A. Ocana, E. Amir and I.F. Tannock, Annals of oncology (PDF) Of the 164 studies included in a literature review of Phase III randomized, clinical trials (RCTs) from 1995 to 2011, . . . → Read More: Bias in reporting of end points of efficacy and toxicity
“Time lag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom, and Denmark. By S.J. Lee and colleagues, British Medical Journal. Clinical practice guidelines recommend targeting breast and colorectal cancer screening to healthy older patients who have a substantial life expectancy. Cancer screening is . . . → Read More: Patients with life expectancy of less than 10 years derive little benefit from screening
“NCI Cancer Bulletin Suspends Publication, National Cancer Institute. As of January 8, 2013, the NCI Cancer Bulletin has suspended publication. A searchable archive of more than 5,000 news and feature stories published since 2004 will remain on NCI’s website. Featured clinical trials and summaries highlighting recent results from cancer clinical trials will continue to be . . . → Read More: NCI Cancer Bulletin Suspends Publication
“Breast Screening Costs High for Seniors.” By Nancy Walsh, MedPage today Costs associated with screening for breast cancer among older women remain high, with considerable geographic variation as well as some potentially undesirable implications for diagnosis, a retrospective study found. The annual cost to Medicare for breast cancer screening among women 66 and older was . . . → Read More: Breast Screening Costs High for Seniors
“Billions Paid Out for Surgical Errors.” By Cole Petrochko, MedPage Today Surgical “never events” — such as leaving a sponge in a patient — cost healthcare professionals a minimum of $1.3 billion in malpractice payouts from 1990 to 2010, researchers found. In an analysis of such surgical mishaps, a mean of $133,055 per event was . . . → Read More: Billions Paid Out for Surgical Errors
“Pfizer to Pay $55M for Illegally Promoting Off-Label Use of Drug.” Press Release, United States Department of Justice Pfizer Inc. will pay $55 million plus interest to resolve allegations that Wyeth LLC illegally introduced and caused the introduction into interstate commerce of a misbranded drug, Protonix, between February 2000 and June 2001, the Justice Department . . . → Read More: Pfizer to Pay $55M for Illegally Promoting Off-Label Use of Drug
“People Living Longer but Not Healthier Lives.” By David Pittman, MedPage Today Americans are living longer thanks to advances in medical care, but have a lower quality of life with the proliferation of chronic disease and preventable illness. While deaths from cancer and cardiovascular causes continue to drop, more people are living with diabetes, hypertension, . . . → Read More: People Living Longer but Not Healthier Lives
“The Risk-Benefit Calculation of Mammograms.” By Christie Aschwanden, Slate Last week on Slate, physician Meri Kolbrener lamented that she didn’t have a good way to explain the latest evidence on mammography to her patients. When patients ask her if they should get a mammogram, Kolbrener’s answer is, “I don’t know.” Kolbrener is correct that the . . . → Read More: The Risk-Benefit Calculation of Mammograms |
||
| Copyright © 2026 Breast Cancer Consortium – Archives - All Rights Reserved. Privacy Policy | ||